WO2017101881A1 - 银杏内酯b衍生物及其制备方法与应用 - Google Patents
银杏内酯b衍生物及其制备方法与应用 Download PDFInfo
- Publication number
- WO2017101881A1 WO2017101881A1 PCT/CN2016/110802 CN2016110802W WO2017101881A1 WO 2017101881 A1 WO2017101881 A1 WO 2017101881A1 CN 2016110802 W CN2016110802 W CN 2016110802W WO 2017101881 A1 WO2017101881 A1 WO 2017101881A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- group
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 0 C[C@@]([C@@]([C@@]([C@@]([C@@]1(C(C[C@]2C(C)(C)C)OC3=O)C22[C@]4OC*)O)O5)([C@]13O[C@]2OC4=O)O)C5=O Chemical compound C[C@@]([C@@]([C@@]([C@@]([C@@]1(C(C[C@]2C(C)(C)C)OC3=O)C22[C@]4OC*)O)O5)([C@]13O[C@]2OC4=O)O)C5=O 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the invention relates to a ginkgolide B derivative and a preparation method and application thereof.
- Ginkgolide B (GB) is one of the main active ingredients extracted from Ginkgo biloba leaves. It is also the strongest platelet activating factor (PAF) antagonist discovered so far, which can inhibit platelet aggregation, anti-inflammatory, anti-shock, It is an effective drug for the treatment of acute and chronic cerebral ischemic diseases, such as protecting cardiovascular and cerebrovascular diseases and treating acute pancreatitis.
- PAF platelet activating factor
- ginkgolide B is a six-ring cage-like diterpene compound with a rigid structure, poor water solubility, and low bioavailability, which limits the full effect of the drug and affects its clinical application.
- Patent CN1837212A also reported structural modification of the 10-O position of ginkgolides B, and obtained a series of carboxylic acids and nitrogen-containing derivatives, but the lack of detection data on the improvement of water solubility and pharmacodynamic activity. Therefore, it is necessary to further structurally modify the ginkgolides B lead compound based on previous studies, in order to find a higher activity, better water solubility, and novel structure of the ginkgolide B drug candidate for use in application. Prevention and treatment of cardiovascular and cerebrovascular diseases.
- the object of the present invention is to provide a novel structure of medicinal ginkgolides B derivative, a preparation method and application thereof, and a pharmaceutical composition comprising the ginkgolides B derivative for prevention, treatment and treatment And / or reduce cardiovascular and cerebrovascular diseases provide more options for drug selection.
- R 1 is selected from pyrazinyl or substituted pyrazinyl
- R 2 is selected from pyrazinyl or substituted pyrazinyl, phenyl or substituted phenyl, alkyl or substituted alkyl.
- R 11 , R 12 and R 13 are respectively or simultaneously selected from H, an alkyl group, a substituted alkyl group, an ester group, an alkoxy group, a halogen group, a hydroxyl group, a cyano group, a phenyl group or a substituted phenyl group.
- R 11 , R 12 and R 13 are each independently or simultaneously selected from a C 1 -C 6 alkyl group or a halogen-substituted C 1 -C 6 alkyl group.
- R 21 , R 22 , R 23 are respectively or simultaneously selected from H, alkyl, substituted alkyl, ester, alkoxy, halogen, hydroxy, cyano, phenyl or substituted phenyl;
- R 31 , R 32 , R 33 , R 34 , R 35 are respectively or simultaneously selected from H, alkyl, substituted alkyl, ester, alkoxy, halogen, hydroxy, cyano, phenyl or substituted Phenyl group;
- R 41 , R 42 , R 43 , R 44 , R 45 are respectively or simultaneously selected from H, alkyl, substituted alkyl, ester, alkoxy, halogen, hydroxy, cyano, phenyl or substituted Phenyl.
- R 21 , R 22 and R 23 are each independently or simultaneously selected from a C 1 -C 6 alkyl group or a halogen-substituted C 1 -C 6 alkyl group.
- R 31 is selected from an ester group or an ester group-substituted alkyl group, and R 32 , R 33 , R 34 and R 35 are both H.
- R 31 is selected from a C 2 -C 6 ester group or an ester group-substituted alkyl group as shown in the formula A:
- R 311 and R 312 are each independently or simultaneously selected from a C 2 -C 6 ester group or a C 1 -C 6 alkyl group, and R 311 and R 312 are not simultaneously a C 1 -C 6 alkyl group.
- R 41 , R 42 , R 43 , R 44 and R 45 are respectively or simultaneously selected from H or halogen.
- the pharmaceutically acceptable salt is selected from the group consisting of an organic acid salt or a mineral acid salt.
- the organic acid salt is selected from the group consisting of methanesulfonate, p-toluenesulfonate, besylate, lactate, citrate (citrate), succinate, oxalate, malate, Fumarate, maleate, tartrate, acetate, propionate or succinate;
- the mineral acid salt is selected from the group consisting of hydrochloride, sulfate, hydrobromide or phosphate.
- the invention also provides a preparation method of the compound represented by the above formula Ia, comprising the following steps:
- the ginkgolide B is dissolved in an organic solvent, added The inorganic base and the catalyst are reacted at 50 ° C to 60 ° C to obtain a reaction liquid; wherein X is a halogen;
- step a
- the ginkgolides B and The molar ratio is 1:2 to 1:3; the molar ratio of the ginkgolides B to the inorganic base is 1:10 to 1:20.
- the organic solvent is selected from acetonitrile or N,N-dimethylformamide
- the inorganic base is selected from potassium carbonate, sodium carbonate or cesium carbonate
- the catalyst is potassium iodide.
- the invention also provides a preparation method of the compound of the above formula IIa, IIb or IIc, comprising the following steps:
- the ginkgolide B and the compound represented by the formula V are dissolved in an organic solvent, a catalyst and a condensing agent are added, and the reaction is carried out at 20 ° C to 30 ° C for 4 h to 6 h to obtain a reaction liquid;
- the reaction solution obtained in the step 1 is separated and purified to obtain a compound of the formula IIa, the formula IIb or the formula IIc.
- the molar ratio of the ginkgolide B and the compound represented by the formula V is 1:1 to 1:5; the molar ratio of the ginkgolide B to the catalyst is 1:0.1 to 1:0.3; the ginkgolide The molar ratio of B to the condensing agent is from 1:1.2 to 1:1.6.
- the organic solvent is selected from acetonitrile or N,N-dimethylformamide
- the catalyst is selected from 4-dimethylaminopyridine or 1-hydroxybenzotriazole
- the condensing agent is selected from 1-(3- Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, dicyclohexylcarbodiimide or diisopropylcarbodiimide.
- the present invention also provides a pharmaceutical composition prepared by using the compound of the above formula I or formula II or a pharmaceutically acceptable salt thereof as an active ingredient, together with a pharmaceutically acceptable adjuvant or auxiliary ingredient. Preparation.
- the invention also provides the use of a compound of formula I or formula II above, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment and/or prevention of cardiovascular and cerebrovascular diseases.
- cardiovascular and cerebrovascular diseases include hypertension, stroke, coronary heart disease, arrhythmia, heart failure, dyslipidemia, pulmonary vascular disease, chronic kidney disease, peripheral vascular disease, etc., such as myocardial infarction, coronary artery disease, Atherosclerosis, left main disease, bifurcation lesions, angina pectoris, thrombosis, pulmonary heart disease, endocrine heart disease, anemia heart disease, cardiac neurosis, nutritional metabolic heart disease, aortic aneurysm, lower extremity arteries Sclerosing disease, peripheral arteries Disease, intracranial aneurysm, arteriosclerotic aneurysm, ischemic stroke, hemorrhagic stroke, hyperlipidemia, arteriosclerosis, sudden cardiac death, stroke, vascular embolism, pulmonary embolism, atrial fibrillation, myocardial disease, pericardium Disease, valvular disease, hypertensive encephalopathy, hypertension combined with stroke, cerebral hemorrhage, cerebral
- the myocardial infarction is acute myocardial infarction
- the coronary artery disease is acute coronary syndrome or coronary revascularization
- the hypertension is essential hypertension
- the stroke is Brain stroke
- the arrhythmia is ventricular arrhythmia, complex arrhythmia, hereditary arrhythmia or malignant arrhythmia.
- substitution means that a hydrogen atom in a molecule is replaced by a different atom or molecule.
- the minimum and maximum values of the carbon atom content in the hydrocarbon group are represented by a prefix, for example, the prefix (C a - C b ) alkyl group indicates any alkyl group having "a" to "b" carbon atoms.
- C 1 -C 6 alkyl means an alkyl group containing from 1 to 6 carbon atoms.
- pharmaceutically acceptable means that a carrier, carrier, diluent, adjuvant, and/or salt formed is generally chemically or physically compatible with the other ingredients that constitute a pharmaceutical dosage form, and is physiologically Compatible with the receptor.
- salts and “pharmaceutically acceptable salt” refer to the above-mentioned compounds or stereoisomers thereof, acid and/or basic salts formed with inorganic and/or organic acids and bases, and also includes zwitterionic salts (within Salts) also include quaternary ammonium salts such as alkylammonium salts. These salts can be obtained directly in the final isolation and purification of the compounds. It can also be obtained by mixing the above compound, or a stereoisomer thereof, with a certain amount of an acid or a base as appropriate (for example, an equivalent amount).
- the salt in the present invention may be a hydrochloride, a sulfate, a citrate, a methanesulfonate or a benzenesulfonate of the compound.
- the raw materials and equipment used in the specific embodiments of the present invention are known products and are obtained by purchasing commercially available products.
- Acetylsalicylic acid Chengdu Kelon Chemical Reagent Factory, batch number 2013101601
- Ligustrazine (20.0 g, 0.147 mol), NBS (26.8 g, 0.151 mol), catalyst benzoyl peroxide (0.058 g, 0.232 mmol) and solvent CCl 4 (75.0 mL) were added in a 250 ml three-necked flask. The lamp was irradiated, and the oil bath was heated to 75 ° C for 10 hours. Filtration and removal of the solvent in the filtrate gave a concentrate. Purification by column chromatography gave a pale yellow solid, 2-bromomethyl-3,5,6-trimethylpyrazine, 15.8 g, yield 50%.
- Essential hypertension is a genetically heterogeneous disease in which several genes with weak effects combine to produce high blood pressure and are affected by a range of environmental factors.
- the pathological process of hypertension often involves thickening of the arterial wall, myocardial fibrosis, left ventricular hypertrophy and renal vascular sclerosis, which causes damage to target organs of hypertension, and significantly increases the incidence and mortality of cardiovascular and cerebrovascular events and kidney disease. It is extremely harmful to human beings. Therefore, reasonable control of blood pressure has very important clinical significance.
- Spontaneously hypertensive rats have many similarities with human essential hypertension, including their genetic characteristics, pathogenesis and the occurrence of hypertension complications, so SHR is considered to be a human study.
- the best animal model of essential hypertension has been widely used in the experimental study of the pathogenesis of hypertension and the efficacy of antihypertensive drugs. Therefore, SHR rats were selected as test animals in this experiment.
- Test drugs BZ, BA, BL, BM, BD, GB, purity > 98%.
- 1.2 positive control drugs Captopril Tablets, 25mg / tablet, Shanghai Pu Kang Pharmaceutical Co., Ltd. products, batch number: 101003.
- Test equipment BP-6 non-invasive animal blood pressure measurement system (Chengdu Taimeng Technology Co., Ltd.); FA1004 electronic analysis balance (Shanghai Precision Science Instrument Co., Ltd.).
- Test animals 112 SHR rats of 14 weeks old, male and female, body weight (200 ⁇ 250) g, provided by Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., experimental animal production license number: SCXK (Beijing) 2007-001; 8 healthy Wistar rats of the same age, male and female, body weight (200-250) g, raised by the Animal Center of Nanjing Medical University Supply, experimental animal production license number: SCXK (Su) 2008-0004.
- the rats in each drug group were intragastrically administered according to the above dosages, and the administration volume was 1 mL/100 g body weight.
- the rats in the normal control group and the SHR rat model control group were intragastrically aliquoted with distilled water for 8 weeks.
- the systolic blood pressure of the rat tail artery was measured using a Bp-6 non-invasive blood pressure measurement system. In the rat state, the systolic blood pressure was continuously measured 3 times, and the average value was taken as the pressure measurement result. Observed indicators: 1 single-dose hypotensive effect, blood pressure of the rats before administration, blood pressure at 30, 60, 90, 120 min after the first dose; 2 continuous administration of blood pressure, 1, 7, 13, 19, 25, 35, 49, 56d blood pressure 30 minutes after the drug, repeated measurements 3 times a day, the average value was taken as the final blood pressure value.
- Each drug group was compared with the model control group, ⁇ P ⁇ 0.05, ⁇ ⁇ P ⁇ 0.01.
- Each drug group was compared with the model control group, ⁇ P ⁇ 0.05, ⁇ ⁇ P ⁇ 0.01.
- the ginkgolides B derivatives and salts thereof provided by the present invention have significantly improved water solubility compared with ginkgolides B, and the latter have a good solution to poor water solubility, low bioavailability, and insufficient efficacy. Defects.
- the pharmacodynamic experiments show that the compound of the present invention has significant therapeutic effects on cardiovascular and cerebrovascular diseases, and can be used for preventing and/or treating hypertension, stroke, coronary heart disease, arrhythmia, heart failure, dyslipidemia, pulmonary vascular disease, chronic kidney Disease, peripheral vascular disease, etc., such as myocardial infarction, coronary artery disease, atherosclerosis, left main disease, bifurcation lesion, angina pectoris, thrombosis, pulmonary heart disease, endocrine heart disease, anemia heart disease, Cardiac neurosis, nutritional metabolic heart disease, aortic aneurysm, lower extremity arteriosclerosis, peripheral arterial disease, intracranial aneurysm, arteriosclerotic aneurysm, ischemic stroke, hemorrhagic stroke, hyperlipidemia, arteriosclerosis Sudden death, sudden cardiac death, stroke, hypotension, vascular embolism, pulmonary embolism, atrial fibrillation, hypertensive encephalopathy
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
化合物 | 水中的溶解性(mg/mL) |
银杏内酯B(GB) | 0.11 |
BM | 0.25 |
BM甲磺酸盐 | 4.20 |
BM盐酸盐 | 4.65 |
BZ | 0.30 |
BZ甲磺酸盐 | 5.02 |
BZ盐酸盐 | 5.10 |
BA | 0.22 |
BL | 0.20 |
BD | 0.25 |
Claims (22)
- 根据权利要求2所述的化合物或其药学上可接受的盐,其特征在于:式Ⅰa所示的化合物中,R11、R12、R13分别或同时选自C1~C6烷基或卤素取代的C1~C6烷基。
- 根据权利要求5所述的化合物或其药学上可接受的盐,其特征在于:式Ⅱa所示的化合物中,R21、R22、R23分别或同时选自C1~C6烷基或卤素取代的C1~C6烷基。
- 根据权利要求5所述的化合物或其药学上可接受的盐,其特征在于:式Ⅱb所示的化合物中,R31选自酯基或酯基取代的烷基,R32、R33、R34、R35同时为H。
- 根据权利要求5所述的化合物或其药学上可接受的盐,其特征在于:式Ⅱc所示的化合物中,R41、R42、R43、R44、R45分别或同时选自H或卤素。
- 根据权利要求1~12任意一项所述的化合物或其药学上可接受的盐,其特征在于:所述药学上可接受的盐选自有机酸盐或无机酸盐。
- 根据权利要求14所述的制备方法,其特征在于:步骤a中,有机溶剂选自乙腈或N,N-二甲基甲酰胺;无机碱选自碳酸钾、碳酸钠或碳酸铯;催化剂为碘化钾。
- 根据权利要求17所述的制备方法,其特征在于:步骤①中,银杏内酯B和式Ⅴ 所示化合物的摩尔比为1:1~1:5;银杏内酯B和催化剂的摩尔比为1:0.1~1:0.3;银杏内酯B和缩合剂的摩尔比为1:1.2~1:1.6。
- 根据权利要求17所述的制备方法,其特征在于:步骤①中,有机溶剂选自乙腈或N,N-二甲基甲酰胺;催化剂选自4-二甲氨基吡啶或1-羟基苯并三唑;缩合剂选自1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐、二环己基碳二亚胺或二异丙基碳二亚胺。
- 一种药物组合物,其特征在于:它是以权利要求1~13任意一项所述的化合物或其药学上可接受的盐为活性成分,加上药学上可接受的辅料或辅助性成分制备得到的制剂。
- 权利要求1~13任意一项所述的化合物或其药学上可接受的盐在制备治疗和/或预防心脑血管疾病的药物中的用途。
- 如权利要求21所述的用途,其特征是:所述的药物是治疗和/或预防高血压的药物。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/063,615 US10875874B2 (en) | 2015-12-18 | 2016-12-19 | Ginkgolide B derivative and preparation method and use thereof |
EP16874938.0A EP3381921B1 (en) | 2015-12-18 | 2016-12-19 | Ginkgolide b derivative and preparation method and use thereof |
KR1020187020564A KR102105451B1 (ko) | 2015-12-18 | 2016-12-19 | 징코라이드b 유도체, 그 제조 방법 및 응용 |
JP2018550641A JP6767498B2 (ja) | 2015-12-18 | 2016-12-19 | ギンコライドb誘導物及びその調製方法並びに応用 |
CA3008698A CA3008698C (en) | 2015-12-18 | 2016-12-19 | Ginkgolide b derivative and preparation method and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510961751 | 2015-12-18 | ||
CN201510961751.4 | 2015-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017101881A1 true WO2017101881A1 (zh) | 2017-06-22 |
Family
ID=59055789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2016/110802 WO2017101881A1 (zh) | 2015-12-18 | 2016-12-19 | 银杏内酯b衍生物及其制备方法与应用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10875874B2 (zh) |
EP (1) | EP3381921B1 (zh) |
JP (1) | JP6767498B2 (zh) |
KR (1) | KR102105451B1 (zh) |
CN (1) | CN106892930B (zh) |
CA (1) | CA3008698C (zh) |
WO (1) | WO2017101881A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109988182B (zh) * | 2018-01-02 | 2021-02-19 | 澳门大学 | 银杏内酯b衍生物及其应用 |
CN109464450B (zh) * | 2019-01-08 | 2020-03-31 | 佳木斯大学附属第一医院 | 一种预防和治疗脑卒中的药物及其制备方法 |
CN115109068B (zh) * | 2021-03-19 | 2024-05-24 | 澳门科技大学 | 用于预防或治疗心脑血管疾病的化合物及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003082185A2 (en) * | 2002-03-29 | 2003-10-09 | The Trustees Of Columbia University In The City Of New York | Analogs of terpene trilactones from ginkgo biloba and related compounds and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8725871D0 (en) | 1987-11-04 | 1987-12-09 | Scras | Ginkgolide derivatives |
GB9107425D0 (en) | 1991-04-09 | 1991-05-22 | Scras | Preparation of ginkgolide b |
EP0642515A1 (en) | 1991-09-18 | 1995-03-15 | Sunkyong Industries Co., Ltd. | New ginkgolide derivatives and a process for preparing them |
KR0136986B1 (ko) | 1993-12-31 | 1998-04-25 | 김준웅 | 신규 징코라이드 유도체와 이의 제조방법 |
US6693091B2 (en) | 2002-03-29 | 2004-02-17 | The Trustees Of Columbia University In The City Of New York | Analogs of terpene trilactones from Ginkgo biloba for bioorganic and imaging studies |
CN100445288C (zh) | 2006-04-26 | 2008-12-24 | 秦引林 | 银杏内酯b衍生物及其在制药中的应用 |
CN101880286B (zh) * | 2009-05-08 | 2014-11-12 | 北京美倍他药物研究有限公司 | 银杏内酯b的水溶性氨基酸酯衍生物 |
CN103508981A (zh) * | 2012-06-18 | 2014-01-15 | 北京美倍他药物研究有限公司 | 新的哌嗪衍生物及其医药用途 |
CN104098584B (zh) * | 2013-04-03 | 2017-01-18 | 广东东阳光药业有限公司 | 银杏内酯b衍生物及其在药物中的应用 |
CN103242337B (zh) * | 2013-04-12 | 2015-04-22 | 合肥工业大学 | 一种基于paf/ros双靶点的银杏内酯b衍生物及其制备方法 |
CN105367582B (zh) * | 2014-08-11 | 2019-06-25 | 广东东阳光药业有限公司 | 银杏内酯b衍生物及其在药物中的应用 |
-
2016
- 2016-12-19 WO PCT/CN2016/110802 patent/WO2017101881A1/zh active Application Filing
- 2016-12-19 US US16/063,615 patent/US10875874B2/en active Active
- 2016-12-19 EP EP16874938.0A patent/EP3381921B1/en not_active Not-in-force
- 2016-12-19 CN CN201611177538.5A patent/CN106892930B/zh active Active
- 2016-12-19 CA CA3008698A patent/CA3008698C/en active Active
- 2016-12-19 JP JP2018550641A patent/JP6767498B2/ja not_active Expired - Fee Related
- 2016-12-19 KR KR1020187020564A patent/KR102105451B1/ko active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003082185A2 (en) * | 2002-03-29 | 2003-10-09 | The Trustees Of Columbia University In The City Of New York | Analogs of terpene trilactones from ginkgo biloba and related compounds and uses thereof |
Non-Patent Citations (1)
Title |
---|
WU, ZEYU ET AL.: "Brain-Targeting Research of 10-0-Nicotinate Ginkgolide B: a New Prodrug of Ginkgolide B", MEDICINAL CHEMISTRY RESEARCH, vol. 21, no. 12, 24 December 2011 (2011-12-24), pages 4028 - 4036, XP035126674 * |
Also Published As
Publication number | Publication date |
---|---|
CA3008698A1 (en) | 2017-06-22 |
EP3381921A1 (en) | 2018-10-03 |
CA3008698C (en) | 2020-12-15 |
EP3381921A4 (en) | 2019-10-30 |
CN106892930B (zh) | 2020-02-18 |
CN106892930A (zh) | 2017-06-27 |
JP2019506446A (ja) | 2019-03-07 |
US20190077811A1 (en) | 2019-03-14 |
US10875874B2 (en) | 2020-12-29 |
EP3381921B1 (en) | 2021-02-03 |
KR20180095665A (ko) | 2018-08-27 |
KR102105451B1 (ko) | 2020-04-28 |
JP6767498B2 (ja) | 2020-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102563378B1 (ko) | 2-(1-아실옥시-n-펜틸)벤조산 및 염기성 아미노산 또는 아미노구아니딘이 형성하는 염, 이의 제조 방법 및 용도 | |
US11986453B2 (en) | Stable pharmaceutical composition containing non-steroidal anti-inflammatory drug derivative | |
WO2017101881A1 (zh) | 银杏内酯b衍生物及其制备方法与应用 | |
TW201034664A (en) | Telmisartan acid addition salt | |
JPH01294675A (ja) | 1,4−ジヒドロピリジン誘導体、これらの製造法およびこれらの薬剤としての適用 | |
JP3853389B2 (ja) | 新規の3−フェニルスルホニル−3,7−ジアザビシクロ[3,3,1]ノナン−化合物、その製法及び抗不整脈剤 | |
JP2001504446A (ja) | 血管内皮細胞の損傷から生じる疾患を治療・予防するための医薬品 | |
NO179515B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive 3,4-dihydroisokinolinderivater | |
JP5695797B2 (ja) | 新規抗血小板化合物の付加塩 | |
CN108069980B (zh) | 银杏内酯k新型衍生物及其制备方法和用途 | |
WO2019232662A1 (zh) | 一类具有抗癌活性的吲嗪类化合物及其衍生物 | |
CN107325052A (zh) | 一类具有抗癌活性的咪唑酯类化合物及其衍生物 | |
WO2020249117A1 (zh) | 抗高血压的多元醇化合物及其衍生物 | |
EA006245B1 (ru) | Гидрохлорид 4-[4-(2-пирролилкарбонил)-1-пиперазинил]-3-трифторметилбензоилгуанидина | |
JP2019089822A (ja) | トピロキソスタットの新規結晶形及びその製造方法 | |
JP7473554B2 (ja) | Par4阻害剤の結晶体 | |
JP2020533401A (ja) | 不飽和脂肪族オレフィン性結合を含有するチエノピリジン誘導体、その調製方法および使用 | |
WO2023104201A1 (zh) | 芳基c-葡萄糖苷衍生物、其制备方法及其用途 | |
JPH0647540B2 (ja) | 虚血性心疾患・不整脈治療・予防剤 | |
KR101086899B1 (ko) | 암로디핀-로자탄 다이술폰산염, 이의 제조방법 및 이를 포함하는 약제학적 조성물 | |
WO2020143779A1 (zh) | 泊马度胺前体药物的盐 | |
Liu et al. | Scaffold evaluation of liguzinediol analogs as novel cardiotonic agents | |
CN109705120A (zh) | 一类咪唑并[1,2-a]吡啶化合物及其制备方法和用途 | |
WO2013010502A1 (zh) | 一种普拉格雷的酸加成盐及其制备方法和用途 | |
WO2019232663A1 (zh) | 一类具有抗癌活性的氨基取代吲嗪类化合物及其衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16874938 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3008698 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2018550641 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016874938 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20187020564 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020187020564 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2016874938 Country of ref document: EP Effective date: 20180626 |